UroToday UroToday
  • Contact
  • Login
  • Sign Up Free
Menu
Follow UroToday
  • Articles
    • Urologic Oncology
      • Adrenal Diseases
      • Biomarkers
      • Bladder Cancer
      • Bone Scintigraphy
      • Bone Targeted Treatments
      • CRPC w/ Bone Metastases
      • Immunotherapy PCa
      • mCRPC Treatment
      • Penile Cancer
      • Prostate Cancer
      • Renal Cancer
      • Testicular Cancer
      • Upper Tract Tumors
      • Investigative Urology
    • Men's Health
      • Androgen Deficiency
      • BPH
      • Erectile Dysfunction
      • Male Infertility
      • Peyronie’s Disease
      • Prostatitis
      • Vasectomy
    • Pelvic Health & Reconstruction
      • Fecal Incontinence
      • Fistula
      • GU Trauma & Reconstruction
      • Indwelling Catheters
      • Infections
      • Intermittent Catheters
      • Interstitial Cystitis
      • Neurogenic Bladder
      • Nocturia
      • Overactive Bladder
      • Pelvic Prolapse
      • Post-prostatectomy Incontinence
      • Stress Incontinence
      • Underactive Bladder
      • Urethral Strictures
      • Urinary Incontinence
      • Urinary Retention
      • Urinary Tract Infection – CAUTIs
    • Endourology & Urolithiasis
      • Minimally Invasive Procedures
      • Stone Disease
    • Pediatric Urology
      • Pediatric Urology
    • Urinary Catheters
      • History
      • Intermittent
      • Indwelling
  • Video Lectures
    • EAU 2018 GU Oncology
    • Keane's Corner
    • Advanced Prostate Cancer Consensus Conference: APCCC
    • Advanced Prostate Cancer
    • Bladder Cancer
    • Bladder Health
    • Book Club
    • CRPC w/ Bone Metastases
    • Endourology
    • Hot Topic QuickTakes
    • Immunotherapy PCa
    • LUGPA GU Oncology
    • Nocturia & Lower Urinary Tract Conditions
    • M0 Prostate Cancer
    • mCRPC Treatment
    • Prostate Cancer
    • Radiation: Prostate Cancer
    • Urologic Catheters
  • Clinical Trials
  • Centers of Excellence
      Curated by expert editors: a single source educational forum with lectures, literature and conference information.
    • Advanced Prostate Cancer Alicia Morgans, MD, MPH
    • Bladder Cancer Ashish Kamat, MD
    • Bladder Health Diane K. Newman, DNP, ANP-BC, FAAN
    • CRPC with Bone Metastases Dr. Daniel George
    •  
    • Imaging Center Phillip Koo, MD
    • mCRPC Treatment Charles Ryan, MD
    • M0 Prostate Cancer Neal Shore, MD, FACS
    • Lower Urinary Tract Conditions Benjamin M. Brucker, MD
    •  
  • Conference Highlights
    • APCCC
      • 2017 APCCC
    • AUA
      • 2018 Annual Meeting
      • 2017 Quality Improvement Summit
      • 2017 Annual Meeting
    • Bladder Cancer Think Tank
      • 2016 Bladder Cancer Think Tank
    • EAU
      • ESOU18
      • 2018 Annual Congress
      • 2017 Annual Congress
    • ASCO
      • 2018 ASCO GU Symposium
      • 2017 ASCO GU Symposium
      • 2017 Annual Meeting
      • 2016 Annual Meeting
    • Bladder Cancer Academy
      • 2017 Bladder Cancer Academy
    • Canadian Urological Association Meeting
      • 2017 Annual Meeting
    • ESMO
      • 2017 Annual Congress
    • LUGPA
      • 2016 Annual Meeting
    • WCE & SWL
      • 2017 Annual Meeting
      • 2016 Annual Meeting
    • SIU
      • 2017 Congress
      • 2016 Congress
    • SUFU
      • 2018 Winter Meeting
      • 2017 Winter Meeting
    • SUO
      • 2017 Annual Meeting
      • 2016 Annual Meeting
    • Targeted Alpha Therapy 10
      • TAT-10
    • IPCU
      • 2017 International Prostate Cancer Update
    • IBCN
      • 2017 International Bladder Cancer Network
  • Journals
      Print publications focusing on urological cancer treatments through original commentary & articles
    • Everyday Urology - Oncology Insights
    • Prostate Cancer and Prostatic Diseases
  • Calendar
  1. Home
  2. Urologic Oncology
  3. Immunotherapy

Immunotherapy

Recent Abstracts
View All
  • Immunotherapy
    March 10, 2016
    [Immunotherapy in the treatment of genitourinary cancers].
  • Immunotherapy
    December 9, 2015
    Immunotherapy in prostate cancer: challenges and opportunities.
  • Immunotherapy
    November 15, 2015
    Prospects for the Future of Prostate Cancer Vaccines.
  • Immunotherapy
    November 5, 2015
    Vaccines, Adjuvants, and Dendritic Cell Activators-Current Status and Future Challenges.
  • Immunotherapy
    October 27, 2015
    Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
  • Immunotherapy
    October 6, 2015
    What risk of prostate cancer led urologist to recommend prostate biopsies?
  • Immunotherapy
    October 6, 2015
    Quality of preventive care before and after prostate cancer diagnosis.
  • Immunotherapy
    October 6, 2015
    The clinical role of multimodality imaging in the detection of prostate cancer recurrence after radical prostatectomy and radiation therapy: past, present, and future.
  • Immunotherapy
    October 6, 2015
    PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies.
  • Immunotherapy
    October 6, 2015
    Association of quantitative magnetic resonance imaging parameters with histological findings from MRI/ultrasound fusion prostate biopsy.
View All (10 Pages)
Beyond the Abstracts
View All
  • Immunotherapy
    August 20, 2015
    Exploiting synergy: the promise of immunogenic intensification in the treatment of prostate cancer - Beyond the Abstract
  • Immunotherapy
    March 4, 2015
    Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy "Beyond the Abstract," by Stefanie Mandl, PhD
  • Immunotherapy
    August 21, 2014
    A therapeutic vaccine for prostate cancer: Immune impact induced by PROSTVAC (PSA-TRICOM), "Beyond the Abstract," by James L. Gulley, MD, PhD
  • Immunotherapy
    October 28, 2013
    The Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial: Lower baseline prostate-specific antigen Is associated with a greater overall survival benefit from sipuleucel-T, "Beyond the Abstract," by Philip W. Kantoff, MD
  • Immunotherapy
    April 10, 2013
    Analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer indicates sipuleucel-T immune parameters correlate with survival, "Beyond the Abstract," by Mayer N. Fishman, MD, PhD, et al.
  • Immunotherapy
    August 15, 2012
    Beyond the Abstract - Development of novel immune interventions for prostate cancer, by Neeraj Agarwal and Nicholas J. Vogelzang
View All (1 Page)
  • About UroToday
  • Editorial and Advertising Guidelines
  • Editorial Leadership
  • FAQs
  • Privacy Policy
  • Terms of Use

COPYRIGHT © 2002 - 2018 DIGITAL SCIENCE PRESS, INC.

Follow UroToday

Login

Login to update email address, newsletter preferences and use bookmarks.

  • Forgot Password?
  • Sign Up Free